Drug Profile
Clopidogrel nanosomal - Intas Pharmaceuticals/Jina Pharmaceuticals
Alternative Names: Nanosomal clopidogrelLatest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Intas Pharmaceuticals; Jina Pharmaceuticals
- Class 2 ring heterocyclic compounds; Antiplatelets; Chlorobenzenes; Esters; Pyridines; Small molecules; Thienopyridines
- Mechanism of Action Platelet ADP receptor antagonists; Platelet aggregation inhibitors; Purinergic P2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 28 May 2022 No recent reports of development identified for phase-I development in Cardiovascular-disorders(In volunteers) in USA (IV, Suspension)
- 12 May 2020 Phase-I development is ongoing for Cardiovascular disorders in USA (IV, Suspension) (Jina Pharmaceuticals pipeline, May 2020)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Cardiovascular-disorders(In volunteers) in USA (IV, Suspension)